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Vaccinia virus (VACV) encodes DNA polymerase and
additional proteins that enable cytoplasmic replica-
tion. We confirmed the ability of VACV DNA ligase
mutants to replicate and tested the hypothesis that
cellular ligases compensate for loss of viral gene
expression. RNA silencing of human DNA ligase I
expression and a small molecule inhibitor of human
DNA ligase I severely reduced replication of viral
DNA in cells infected with VACV ligase-deficient
mutants, indicating that the cellular enzyme plays
a complementary role. Replication of ligase-deficient
VACV was greatly reduced and delayed in resting
primary cells, correlating with initial low levels of
ligase I and subsequent viral induction and localiza-
tion of ligase I in virus factories. These studies indi-
cate thatDNA ligation isessential forpoxvirus replica-
tion and explain the ability of ligase deletion mutants
to replicate in dividing cells but exhibit decreased
pathogenicity in mice. Encoding its own ligase might
allow VACV to ‘‘jump-start’’ DNA synthesis.
INTRODUCTION
Poxviruses are large DNA viruses notable for their replication in
the cytoplasm of infected cells, wide distribution in nature, and
ability to cause disease (Moss, 2007). Proteins encoded by
vaccinia virus (VACV), the prototype poxvirus, that are essential
for replication and processing of viral DNA include a DNA
polymerase, primase/NTPase, uracil DNA glycosylase, proces-
sivity factor, protein kinase, and Holliday junction resolvase
(Moss and De Silva, 2006). Chordopoxviruses also encode an
ATP-dependent DNA ligase that is expressed early in infection
(Colinas et al., 1990; Kerr and Smith, 1989; Smith et al., 1989).
The VACV DNA ligase, which can repair nicked duplex DNA
substrates consisting of a 50 phosphate terminated strand and
a 30-hydroxyl terminated strand, has been characterized
extensively (Sekiguchi and Shuman, 1997).
Deletion of theDNA ligase gene fromVACV andShope fibroma
virus had minor effects on replication (Colinas et al., 1990; Kerr
and Smith, 1991; Parks et al., 1998), although the sensitivity of
the mutant viruses to DNA-damaging agents was increasedCell Host &(Kerr et al., 1991; Parks et al., 1998). The viability of the ligase
mutant virus could be interpreted as support for an asymmetric
DNA replication model, which posits only leading-strand DNA
synthesis (Moss and De Silva, 2006; Moyer and Graves, 1981).
However, the recent discovery of a VACV DNA primase (De Silva
et al., 2007, 2009) has led to renewed interest in aDNA replication
model that requires joining of Okazaki fragments on the lagging
strand at the replication fork (Esteban and Holowczak, 1977;
Olgiati et al., 1976). If the latter model is correct, then another
unrecognized viral enzyme or a cellular DNA ligase must partici-
pate in DNA replication to compensate for loss of the viral ligase.
Utilization of a cellular ligase was considered, but evidence
for this was not obtained (Kerr et al., 1991). Nevertheless, the
availability of new methods, in particular RNA silencing, as well
as better reagents encouraged us to reopen the question.
Vertebrates possess three homologous DNA ligases: I, III, and
IV (abbreviated as Lig1, Lig3, and Lig4) (Ellenberger and
Tomkinson, 2008). Lig1 participates in DNA replication by joining
DNA fragments during lagging-strand synthesis and also is
involved in DNA repair. Lig3 (and its alternately spliced form,
Lig2) complexes with DNA repair protein XRCC1 to aid in sealing
base excision mutations and recombinant fragments. Lig4
complexes with XRCC4 and catalyzes the final step in nonho-
mologous DNA double-strand break repair. The VACV DNA
ligase is homologous to the eukaryotic DNA ligases at the
DNA-binding and catalytic domains with the greatest similarity
to Lig3 (Wang et al., 1994).
Herewe show that replication of a VACV ligase deletionmutant
in proliferating cells depends on cellular Lig1, which is recruited
from the nucleus to cytoplasmic viral factories. Replication of
ligase-deficient VACVwasgreatly reducedanddelayed in resting
primary cells, correlating with initial low levels of Lig1 and subse-
quent viral induction and localization of that enzyme in virus
factories. The defect in resting cells could explain the decreased
pathogenicity of ligase-deficient VACV in a mouse model (Kerr
et al., 1991). The synthesis of a viral ligase could give VACV
a head start in replication and contribute to pathogenicity.RESULTS
Lig1 Contributes to the Replication of DNA
Ligase-Deficient VACV
We constructed several recombinant VACVs. First, we replaced
the A50R open reading frame (ORF) encoding DNA ligase withMicrobe 6, 563–569, December 17, 2009 ª2009 Elsevier Inc. 563
Figure 1. Knockdown of Cellular Lig1 Inhibits Replication of VACV Ligase Deletion Mutant
(A) Knockdown of cellular DNA ligases. HeLa cells were transfected with siRNAs to Lig1, Lig3, or Lig4 or a control nontargeting RNA. After 72 hr, cell lysates were
analyzed by western blotting with antibodies to Lig1, Lig3, and Lig4, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.
Antibody binding was detected by chemiluminescence.
(B) Effects of siRNAs on replication of mutant and wild-type VACV. HeLa cells were transfected with siRNAs to Lig1, Lig3, or Lig4 or with a control nontargeting
siRNA. After 72 hr, the cells were infected with 4 pfu per cell of vDA50gfp or vA50Rev. At indicated times, virus titers were determined by plaque assay (upper
panels) or viral DNA was quantified by real-time PCR (lower panels). Experiments were in triplicate, and bars represent standard error of the mean.
(C) Effect of Lig1 knockdown on late gene expression. HeLa cells were transfected with ligase-specific or control siRNA. After 72 hr, the cells were infected with
4 pfu per cell of vDA50gfp and visualized by fluorescence microscopy at indicated times.
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Cellular DNA Ligase I Recruited by Vaccinia Virusthat of enhanced green fluorescent protein (GFP) regulated by
a VACV late promoter to form vDA50gfp. Then we made
additional recombinants by replacing the GFP gene and
promoter with an intact A50RORF to form the revertant vA50Rev
or with one containing a stop codon to form vA50Stop. The latter
two constructs had the natural promoter upstream of the A50R
ORF. The phenotypes of the revertant and stop codon viruses
were similar to those of the wild-type parent and the deletion
mutant, respectively (see Figure S1A available online). The
mutant viruses replicated in a variety of cell lines with at most
a half-log reduction in yield compared to the revertant
(Figure S1A). Similarly, DNA replication of mutant viruses deter-
mined by slot blot analysis and real-time PCR was unaffected or
modestly reduced (Figure S1B). Overall, these results were
consistent with previous reports (Kerr and Smith, 1991; Parks
et al., 1998) indicating that ligase-deficient VACV can replicate
in proliferating cell lines.
In order to investigate a role for a cellular DNA ligase in
supporting replication of DNA ligase-deficient VACV, we used
siRNAs to Lig1, Lig3, and Lig4 mRNAs that had been previously564 Cell Host & Microbe 6, 563–569, December 17, 2009 ª2009 Elseshown to knock down their expression in human cells (Muylaert
and Elias, 2007). Transfection of each siRNA knocked down the
corresponding mRNA by 45%–70% (data not shown), which
resulted in a concomitant target-specific reduction in the ligase
protein (Figure 1A). Next we determined the effect of knocking
down cellular DNA ligases on replication of VACV. The yield of
infectious vDA50gfp was reduced approximately 1 log by siRNA
to Lig1, but not by siRNA to Lig3 or Lig4 (Figure 1B, upper left).
None of the siRNAs strongly inhibited replication of vA50Rev
(Figure 1B, upper right), indicating that Lig1 was only required
in the absence of the viral ligase. Control experiments demon-
strated that the reduction in VACV replication caused by Lig1
siRNA could be partially alleviated by transfection of plasmids
expressing Lig1 that was resistant to the siRNA because of silent
mutations or VACV DNA ligase (Figure S2).
Real-time PCRwas used to determine the effect of the siRNAs
on viral DNA replication. Inhibition was specific for siRNA to Lig1
and occurred in cells infected with vDA50gfp (Figure 1B, lower
left), but not with vA50Rev (Figure 1B, lower right). The inhibition
by Lig1 siRNA in cells infected with vDA50gfp was more severevier Inc.
Figure 2. Effects of Ligase Inhibitors
HeLa cells were treated with 50 mM L82 or L67 or with dimethylsulfoxide
(DMSO) carrier for 48 hr and then infected with 4 pfu per cell of vDA50gfp or
vA50Rev. At 24 hr after infection, the cells were harvested and the virus titers
determined by plaque assay. Bars represent standard errors of the mean.
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hr under these conditions but reached a maximum by 12 hr and
plateaued in the control infected cells. At 13 hr after infection,
genome size vDA50gfp DNA was almost undetectable by
pulse-field gel electrophoresis and Southern blotting following
knockdown of DNA Lig1 but not the other cellular ligases, further
substantiating the above results (data not shown).
We took advantage of the presence of GFP regulated by the
VACV late p11 promoter in vDA50gfp to determine the effects
of the siRNA on viral late protein synthesis, which is dependent
on viral DNA replication. Cells transfected with control siRNA
or siRNA to Lig3 or Lig4 and infected with vDA50gfp exhibited
green fluorescence at 8 hr, which increased greatly with time
(Figure 1C). In contrast, few cells that had been transfected
with siRNA to Lig1 showed green fluorescence at 8–12 hr, and
the fluorescence was markedly less than the control even at 24
hr (Figure 1C). The latter result was consistent with the effect
of siRNA to Lig1 on viral DNA replication in cells infected with
the A50 deletion mutant.
Inhibitor of Lig1 Reduces vDA50gfp Replication
We tested the effects of the small molecule inhibitor L82, specific
for Lig1, and L67, which inhibits Lig1 and Lig3 (Chen et al., 2008).
Inhibition of Lig1 resulted in about 90% inhibition of replication of
vDA50gfp but had almost no effect on the replication of the
revertant virus (Figure 2). The less specific ligase inhibitor L67,
however, reduced the replication of vDA50gfp and the revertant
virus (Figure 2). Thus, use of the small molecule inhibitor L82
supported a role of Lig1 in compensating loss of the viral ligase.
Replication of VACV in Resting Cells Requires Viral
DNA Ligase
Unlike the situation in the laboratory, where cell lines are actively
replicating, cells in vivo are mostly in a resting state. Moreover,
Lig1 is the predominant DNA ligase in proliferating cells, whereas
the other ligases are predominant in resting cells (Lindahl and
Barnes, 1992; Montecucco et al., 1992). Comparison of the level
of DNA ligases in proliferating and resting primary human
foreskin fibroblasts (HFFs) with ligase-specific antibodies
confirmed that the level of Lig1 was much lower under the latterCell Host &conditions, whereas the amounts of Lig3 and Lig4 were similar
(Figure 3A). Moreover, proliferating HFF cells supported the
replication and spread of vDA50gfp more highly than did resting
HFF cells, as indicated by GFP expression (Figure 3B).
A time course analysis further indicated that replication and
spread of vDA50gfp was greatly reduced and delayed in resting
HFF cells: at 24 and 48 hr, the virus yields were about 2 logs
lower than in proliferating cells, but the difference narrowed to
about 1 log at 72 hr (Figure 3C). Furthermore, the yield of
vA50Rev was 2 logs higher than vDA50gfp at 24 hr, indicating
that the low replication of vDA50gfp was largely due to the
deletion of the viral ligase (Figure 3C). A similar pattern was
seen when viral DNA was measured. DNA synthesis with
vDA50gfp was higher in proliferating cells than in resting cells
and lagged behind that of vA50Rev in the latter (Figure 3D). In
addition, the rise in viral DNA synthesis in resting cells infected
with vDA50gfp preceded that of infectious virus (Figure 3D).
VACV Induces Lig1 in Resting Cells
We considered that the delayed rise in vDA50gfp replication in
resting HFF cells might be due to induction of Lig1. To check
this possibility, resting and proliferating HFF cells were infected
with vDA50gfp or left uninfected, and Lig1 levels were deter-
mined after 48 hr by western blotting. Indeed, Lig1 was detected
in resting as well as proliferating cells following infection with
vDA50gfp, whereas only the uninfected proliferating cells had
detectable Lig1 (Figure 3E).
Lig1 Is Recruited to the Viral Factory
To determine the intracellular location of Lig1, we used the same
mAb shown to be specific for Lig1 by western blotting (Figures
1A and 3A) and used previously for nuclear staining of replicating
MCF-7 cells (Johansson et al., 2008). In uninfected HeLa cells,
the Lig1 mAb showed predominant nuclear staining with some
juxtanuclear staining that could represent aggresomes
(Figure 4A). Following low multiplicity infection of HeLa cells
with VACV, cytoplasmic factories in infected cells were visual-
ized by staining with DAPI and with rabbit polyclonal antibody
to the VACV A11 protein (Figure 4B). In addition to nuclear stain-
ing, the mAb to Lig1 stained factories in cells infected with
vDA50gfp and vA50Rev (data not shown).
Similar experiments were carried out with HFF cells. In
uninfected proliferating HFF cells, Lig1 was predominantly
nuclear, as was seen with HeLa cells (data not shown). In the
resting state, the stain was more diffusely located over the entire
cell, and cytoplasmic ribbon-like structures that could represent
aggresomes were frequently more prominent than in prolifer-
atingHFF cells (Figure 4C). At 48 hr after infectionwith vDA50gfp,
Lig1 was induced and associated with cytoplasmic factories as
well as the nucleus (Figure 4D). The aggresome-like staining
was less pronounced following virus infection but contained faint
DAPI staining that could represent sequestered viral DNA.
Similar results were obtained at 24 hr, though the factories
were smaller and less abundant and the staining of both Lig1
and the A11 was weaker (data not shown). Association of Lig1
with factories could also be seen in resting HFF cells that were
infected with vA50Rev (Figure 4E), suggesting that induction of
Lig1 may be important for wild-type VACV infections in resting
cells.Microbe 6, 563–569, December 17, 2009 ª2009 Elsevier Inc. 565
Figure 3. Analysis of Cellular Ligases and Replication of vDA50gfp Ligase Deletion Mutant in Resting and Proliferating HFF Cells
(A) Cellular ligases in resting and proliferating cells. HFF cells were maintained in medium containing 0.2% FBS for 4 days to induce the resting state or were
passaged in medium containing 10% FBS to allow proliferation. The cells were lysed and the proteins analyzed by western blotting with antibodies to Lig1,
Lig3, or Lig4 or to b-actin and detected by chemiluminescence.
(B) VACV late gene expression. Resting and proliferating HFF cells were infected with 0.02 pfu per cell of vDA50gfp. After 48 hr, the cells were visualized by fluo-
rescence microscopy (green) and after 72 hr by light microscopy after crystal violet staining (black and white).
(C and D) Virus replication and DNA synthesis. Resting and proliferating HFF cells were infected with 0.02 pfu per cell of vDA50gfp or vA50Rev. At indicated times,
virus titers were determined by plaque assay or viral DNA was quantified by real-time PCR. Experiments were in duplicate, and bars indicate standard error.
(E) Induction of Lig1 in resting cells by VACV. Lig1 and GAPDH were analyzed by western blotting of extracts from resting and proliferating HFF cells that were
uninfected or infected with vDA50gfp for 48 hr.
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The role of the VACV DNA ligase has remained ambiguous since
its discovery 20 years ago (Colinas et al., 1990; Kerr and Smith,
1989; Smith et al., 1989). In most cell lines, DNA ligase deletion
mutants replicate as well or nearly as well as wild-type virus,
and the only consistent defect is enhanced sensitivity to DNA-
damaging agents (Kerr et al., 1991; Parks et al., 1998). If DNA liga-
tion were truly not required, as could be inferred from the above
results, it would rule out poxvirus DNA replication mechanisms
involving lagging-strand synthesis. Here we showed that the
apparent dispensability of DNA ligation is due to the ability of
a cellular ligase to compensate for loss of the viral enzyme. Func-
tional utilization of a cellular ligasewasdemonstratedwith siRNA,
a smallmolecule inhibitor, and restingcells; associationof cellular
ligase with viral factories was shown by confocal microscopy.
It had been noted previously that poxvirus ligases are more
closely related in sequence to Lig3 than to Lig1 or Lig4 (Wang566 Cell Host & Microbe 6, 563–569, December 17, 2009 ª2009 Elseet al., 1994). However, we found that only knockdown of Lig1
inhibited the replication of a VACV ligase deletion mutant and
that this occurred at the level of viral DNA synthesis. In addition,
the specific Lig1 inhibitor L82 (Chen et al., 2008) severely
reduced replication of vDA50gfp. A second inhibitor, L-67, which
has less specificity (Chen et al., 2008), reduced replication of
both ligase deletion mutant and wild-type VACV. However, it is
not known whether L-67 inhibits the VACV DNA ligase. From
a functional point of view, it makes sense that Lig1 can substitute
for the VACV ligase, since Lig1 is mainly involved in DNA replica-
tion (Ellenberger and Tomkinson, 2008). With the same set of
siRNAs used here, however, Muylaert and Elias (Muylaert and
Elias, 2007) found that knockdown of Lig4, but not Lig1 or
Lig3, in human cells inhibited herpes simplex virus 1 DNA
replication. They suggested that Lig4 is needed for joining to
make herpes simplex virus circular DNA templates, leaving
open the question of which ligase is involved in lagging-strand
DNA synthesis in that system.vier Inc.
Figure 4. Detection of Lig1 in Cytoplasmic
VACV Factories
Uninfected HeLa cells (A) or HeLa cells infected
with vDA50gfp for 12 hr (B) were stained with
mousemAb to Lig1 and rabbit polyclonal antibody
to the VACV A11 protein followed by secondary
fluorescent antibodies and DAPI. Resting HFF
cells were uninfected (C) or infected with
vDA50gfp for 48 hr (D) or vA50Rev for 24 hr (E)
and stained as for (A) and (B). Arrowheads point
to cytoplasmic factories.
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nuclear localization of Lig1 in replicating cells (Johansson
et al., 2008; Lasko et al., 1990) and discovered that Lig1 localized
in cytoplasmic viral factories in cells infected with a VACV ligase
deletion mutant as well as with wild-type virus. In uninfected
replicating cells, Lig1 localizes to nuclear foci of DNA replication
through interaction with proliferating cell nuclear antigen (PCNA)
(Montecucco et al., 1998). Both Lig1 and PCNA are part of a large
complex with other proteins involved in Okazaki fragment forma-
tion and processing (Applegren et al., 1995). Whether PCNA and
other nuclear proteins accompany Lig1 to viral factories and
whether Lig1 interacts with some viral protein(s) remain to be
determined. VACV ligase has been shown to interact with cellular
topoisomerase II and recruit the latter to viral factories (Lin et al.,
2008). Coincidently, it has been suggested that topoisomerase II
also interacts with PCNA (Niimi et al., 2001). A variety of addi-
tional cellular proteins including translation initiation and tran-
scription factors have been shown to localize in virus factories
(Broyles, 1991; Katsafanas and Moss, 2007; Walsh et al.,Cell Host & Microbe 6, 563–569, D2008). Whether the latter proteins simply
associate with viral DNA and RNA or
have specific viral protein-binding
partners is not known.
Replication of the VACV ligase deletion
mutant was not inhibited or onlymodestly
inhibited in all proliferating cell lines
tested. The better replication of ligase-
deficient VACV in BS-C-1 cells compared
to HeLa cells (Figure S1) correlated with
a relatively higher level of Lig1 compared
to Lig4 in the former (T.G.S., unpublished
data), but other contributing factors
cannot be ruled out. If Lig1 can compen-
sate for the viral ligase, why does VACV
encode its own ligase? An answer came
from studies with resting primary cells,
which exhibited a specific deficiency in
Lig1 but not Lig3 or Lig4. Replication of
vDA50gfp was severely impaired and de-
layed compared to a control VACV that
expressed the viral ligase. Thus, the viral
ligase provides an important advantage
in resting cells. Interestingly, the delayed
onset of replication of ligase-deficient
virus corresponded to the induction of
Lig1 shown by western blotting and thelocalization of Lig1 in cytoplasmic virus factories. The mecha-
nism of Lig1 induction by VACV remains to be determined.
The opposite question to the one posed above is whether
there is an advantage for wild-type VACV to recruit the cellular
ligase when it encodes its own. While additional ligase may be
beneficial, another possibility is that Lig1 brings along an
associated cellular protein. The plasticity of DNA ligase usage
is underscored by the fact that, although an ATP-dependent
ligase was likely encoded by the common ancestor of all eukary-
otic nucleocytoplasmic large DNA viruses (Iyer et al., 2001), this
gene was lost in several chordopoxviruses (molluscipoxvirus,
parapoxviruses, and yatapoxviruses) and replaced by an NAD-
dependent ligase in entomopoxviruses.
Our data can explain the previously described decreased
pathogenicity of a VACV ligase deletion mutant (Kerr et al.,
1991), since the majority of cells in an animal are in the quiescent
state and consequently have low levels of Lig1 (Vitolo et al.,
2005). The early expression of the viral ligase presumably
provides VACV with a head start in DNA replication.ecember 17, 2009 ª2009 Elsevier Inc. 567
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Cells and Virus
HeLa cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM,
Quality Biologicals, Inc., Gaithersburg,MD) containing 10% fetal bovine serum
(FBS). HFF cells were maintained as previously described (De Silva and Moss,
2008) and seeded into 6-well tissue culture plates in DMEM supplemented
with 10% FBS. When monolayers were confluent, culture medium was
replaced with fresh medium supplemented with 0.2% FBS and maintained
for 96 hr to induce the resting state. HFF cells were infected with virus using
0.2% FBS-supplemented medium. Alternatively, cells were passaged with
10% FBS and as soon as they were confluent were infected with virus in
2.5% FBS-supplemented media.
Antibodies
Antibodies used were the following: mouse anti-Lig1 (clone 10H5) (Santa Cruz
Biotechnology, Santa Cruz, CA), mouse anti-Lig3 (Abcam, Cambridge, UK)
and rabbit anti-lig4 (Proteintech Group Inc, Chicago, IL), mouse anti-glyceral-
dehyde-3-phosphate dehydrogenase (Abcam), mouse anti-a-actin (Santa
Cruz Biotechnologies), goat anti-mouse IgG conjugated to horseradish
peroxidase, goat anti-rabbit IgG conjugated to horseradish peroxidase
(Santa-Cruz Biotechnologies), rabbit polyclonal anti-VACV A11 (Resch et al.,
2005), and Alexa Fluor 594 and Alexa Fluor 633 conjugated to anti-IgG of
appropriate species (Molecular probes, Eugene, OR).
siRNAs
Double-stranded siRNAs specific for Lig1, Lig3, and Lig4 (Lig1, 50-AAGGG
CAAGACAGCAGAGGCC; Lig3, 50-AACUGCAACCCAGAUGAUAUG; Lig4,
50-AAGCCAGACAAAAGAGGUGAA) with dT dinucleotides added at the 30
ends (Muylaert and Elias, 2007) and control nontargeting siRNA were
purchased from Dharmacon (Lafayette, CO).
Recombinant Viruses
Recombinant viruses were constructed as described (Earl et al., 1998a,
1998b), except that DNA made by overlapping PCR (Senkevich et al., 2000)
was used for homologous recombination. vDA50gfp was constructed by
replacing the A50R ORF with the GFP ORF controlled by the VACV P11
promoter. DNA containing part of the A49R ORF, the VACV P11 promoter
and GFP ORF, and VACV A51R sequences were prepared and assembled
into a single A49-p11GFP-A51 PCR product. BS-C-1 cells infected with
VACV were transfected with the DNA, and plaques containing recombinant
viruses were identified by green fluorescence and clonally purified. vA50Rev
was constructed by replacing the P11 promoter and GFP of vDA50gfp with
the natural A50R sequence. DNA containing the complete A50R ORF and
flanking A49R and A51R sequences was assembled by PCR and transfected
into BS-C-1 cells that were infected with vDA50gfp. Plaques containing
recombinant virus were identified by the absence of green fluorescence.
vA50Stop was made by replacing the P11 promoter and GFP of vDA50gfp
with the A50RORFwith a stop codon located after amino acid 75. Overlapping
PCR products with nucleotides 226–228 of the A50R ORF changed from CTA
to TGA were used to assemble DNA for transfection. Plaques containing
recombinant virus were identified by the absence of green fluorescence.
Virus Yield Experiments
HeLa cells at 90% confluency in 12-well plates were transfected with 170 pmol
of siRNA using Lipofectamine 2000 (Invitrogen) in triplicate. After 72 hr, the
cells were infected with 0.25 or 4 pfu of virus per cell and maintained at 4C
for 1 hr. Inocula were removed, and cells were washed three times and overlaid
with 2 ml of E-MEM containing 2.5% FBS. The cells were maintained at 37C,
harvested at various times, and disrupted by three cycles of freezing and
thawing and two 30 s bursts of sonication. Virus yields were determined by
titration on BS-C-1 cells.
Real-Time PCR
Cells from one well of a 12-well plate were disrupted by three freeze-thaw
cycles and two 30 s sonications. DNA was isolated with the Blood Mini Kit
(QIAGEN, Hilden, Germany). Reactions were carried out using SYBR Green
PCR master mix (Applied Biosystems), 10 mM of each primer, and 2 ml of568 Cell Host & Microbe 6, 563–569, December 17, 2009 ª2009 ElseDNA in a total volume of 50 ml with the RealPlex sequence detection system
and software (Eppendorf, Westbury, NY). DNA was amplified with 40 cycles
at 95C for 15 s and 55C for 60 s. For determination of genome equivalents,
standard curves were made using DNA from virus of known titer assuming 50
particles per pfu.
Western Blot
Lysates from 106 cells were treated with micrococcal nuclease (Worthington,
Lakewood, NJ) for 30 min on ice in buffer containing 10 mM NaCl, 10 mM
Tris-HCl (pH 7.4), 10 mM CaCl2, and 0.2% NP40 followed by three 30 s
sonications. Proteins were separated on 4%–12% SDS NuPage gel (Invitro-
gen) and transferred to a nitrocellulose filter. After binding primary and
secondary antibodies, SuperSignal West Femto chemiluminescent substrate
was used for detection (Pierce Biotechnology, Rockford, IL).
DNA Ligase Inhibitors
The chemical inhibitors L82 and L67 (Chen et al., 2008) were dissolved in
dimethylsulfoxide at 50 mM and stored at 80C. Confluent monolayers of
HeLa cells were pretreated for 48 hr with 50 mM L82 or L67 or mock treated
with dimethylsulfoxide in DMEM supplemented with 10% FBS. After 48 hr,
the cells were infected with 4 pfu per cell of VACV in E-MEM supplemented
with 2.5% FBS and 50 mM inhibitor. The cells were collected at 24 hr after
infection, and the virus titers were determined by plaque assay after at a dilu-
tion of at least 4 logs to reduce the concentration of inhibitor.
Confocal Microscopy
HFF cells on glass coverslips were allowed to replicate or rest by serum
starvation (0.2% FBS) for 96 hr. HeLa cells were allowed to reach 70% conflu-
ence and then infected or transfected with siRNA for 60 hr before infection.
Cells were fixed with paraformaldehyde, permeabilized with Triton X-100,
and blocked with phosphate-buffered saline (PBS) containing 1% bovine
serum albumin for 1 hr at room temperature. Primary antibodies were
incubated overnight at 4C; after washing, secondary antibody was added
for 45 min at room temperature. DAPI was added at a 5 mg/ml for 20 min at
room temperature, and the cells were washed and mounted with ProLong
Gold antifade reagent (Invitrogen). Images were collected on a Leica SP2
AOBS confocal microscope (Leica Microsystems, Bannockburn, IL). Fluoro-
chromes were excited using 405 nm for DAPI, 594 nm for Alexa Fluor 594,
and 630 nm for Alexa Fluor 647. Detector slits were configured to minimize
crosstalk between the channels.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and two
figures and can be found with this article online at http://www.cell.com/
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